Clinical trials: Estrogens
Periodontal Diseases, Periodontal Pocket
Predictors of Periodontal Outcomes Post-sanative Therapy
Periodontal disease is a chronic inflammatory disease of the tissues surrounding the teeth and is one of the leading causes of tooth loss.
- Trial name
- NCT04639661
- Where
- 2 sites in Canada
- Volunteers
- 12 people
- Sponsor
- Brock University
Sleep Apnea, Post Menopausal
Impact of Estrogen + Estradiol Receptor Alpha Modulator Therapy on Oxidative Stress in Post-menopausal Women With and Without Sleep Apnea
One of the most likely mechanisms explaining the sleep apnea (SA)-induced increase in metabolic syndrome is the oxidative stress (OS) induced by intermittent hypoxia (IH).
- Conditions
- Sleep Apnea, Post Menopausal, Oxidative Stress
- Trial name
- Alpha MenoX (NCT03981341)
- Testing
- Duavive (0.45 estrogens mg and 20 mg bazedoxifene)
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Laval University
Cardiovascular Diseases, Osteoporosis
Macrobiotic Diet and Flax Seed: Effects on Estrogens, Phytoestrogens, & Fibrinolytic Factors
This study will assess whether alternative, high phytoestrogen dietary interventions result in favorable effects on biological parameters that have been associated with hormone-dependent cancers, cardiovascular disease, and…
- Conditions
- Cardiovascular Diseases, Osteoporosis, Breast Cancer, Endometrial Cancer
- Trial name
- NCT00010829
- Testing
- American Heart Association Step 1 diet, American Heart Association Step 2 diet + 10 g/day flax seed, Macrobiotic dietary intervention
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Infertility
Programming by Estrogen Treatment in Gonadotropin Releasing Hormone Antagonist Protocol
The purpose of this study is to determine if pretreatment with Estrogen can assist in the planning and programming of In Vitro Fertilization treatments.
- Trial name
- NCT01419353
- Testing
- estradiol valerate
- Where
- Israel
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Meir Medical Center
Depression, Major Depressive Disorder
Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot Study
The purpose of this study is to determine whether an oxytocin ad-on, or oxytocin and tibolone ad-on can induce a response to antidepressants in patients with treatment resistant depression.
- Trial name
- NCT01239888
- Testing
- Oxytocin, Oxytocin and Tibolone
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- The Alfred
Breast Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
This is a first-in-human, Phase Ia/Ib, dose-escalation and expansion study evaluating the safety, pharmacokinetics, and activity of GDC-0587 (cyclin-dependent kinase-4 [CDK4] inhibitor) as a monotherapy and in combination with…
- Trial name
- NCT07214662
- Testing
- GDC-0587, Giredestrant, Omeprazole
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 3 people
- Sponsor
- Genentech, Inc.
Menopause Syndrome
The Benefits and Risks of Different Menopausal Hormone Replacement Therapy Regimes in the Treatment of Menopause Syndrome
A prospective, open-label, randomized controlled clinical trial to compare the benefits and risks of half-dose or standard-dose conjugated equine estrogens(CEE) plus natural progesterone or dydrogesterone in menopausal hormone…
- Trial name
- NCT03436303
- Testing
- CEE 0.625 mg/MP 100mg, CEE 0.3 mg/MP 100mg, CEE 0.625mg/dydrogesterone
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer
Effect of PPARγ2 Polymorphism and NSAIDs on Acute Alcohol-induced Changes in Serum Estrogens Among Post-menopausal Women
Postmenopausal women, stratified by a peroxisome proliferator-activated receptor gamma-2 (PPARG) polymorphism, were given the following treatments in a random order with a 5w wash-out period: a 400mg ibuprofen tablet or a placebo…
- Trial name
- EPPNASE (NCT02463383)
- Testing
- Ibuprofen Tab 400 MG
- Where
- Denmark
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Professor Lars Ove Dragsted
Endometrial Cancer
Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
The purpose of the protocol is to determine the effect of BN83495 on the progression of endometrial cancer with estrogen receptor in post menopausal women who had previously received chemotherapy.
- Trial name
- NCT01251354
- Testing
- BN83495
- Where
- 9 sites in United States, Canada
- Volunteers
- 6 people
- Sponsor
- Ipsen
Breast Cancer
Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast Cancer
This trial will assess the intratumoural pharmacological activity of BN83495 by changes in intratumoural levels of sex hormones and associated inhibition of steroid sulphatase (STS) activity.
- Trial name
- NCT01230970
- Testing
- BN83495
- Where
- Norway
- Volunteers
- 2 people
- Sponsor
- Ipsen
Prostate Cancer
Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer
The purpose of this study is to see if Premarin is useful against androgen-independent prostate cancer and to help understand how drugs such as Premarin may work.
- Trial name
- NCT00134654
- Testing
- Premarin
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Neoplasms
Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients
The purpose of this study is to examine the immunological response rate to administration of the THERATOPE® vaccine in women with stable metastatic breast cancer who are being treated with aromatase inhibitors or Faslodex® and…
- Trial name
- NCT00046371
- Testing
- THERATOPE® vaccine
- Where
- 17 sites in United States
- Sponsor
- Oncothyreon Canada Inc.
Estrogen Receptor-Positive, HER2-Negative
ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)
For patients with ER-positive, HER2-negative breast cancer, blockage of the ER pathway has been proven to be an effective anticancer approach. These patients showed good response to endocrine therapy.
- Conditions
- Estrogen Receptor-Positive, HER2-Negative, Locally Advanced Breast Cancer, Metastatic Breast Cancer
- Trial name
- ENZENO (NCT04669587)
- Testing
- ZB716, Palbociclib
- Where
- 8 sites in United States, South Korea
- Volunteers
- 106 people
- Sponsor
- EnhancedBio USA Inc.
Alzheimer Disease
Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease
The goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.
- Trial name
- NCT00006399
- Testing
- Donepezil, Estrogen, Progesterone
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Center for Research Resources (NCRR)
Postnatal Depression, Genetic Predisposition
Sequence Variations of Genes in the Estrogen Pathway and Perinatal Depression
To elucidate the disease pathway of perinatal depression by identifying genetic variants which could play a role in predisposing to the condition and/or lead to better understanding of the pathogenesis of the condition.
- Trial name
- NCT02373709
- Where
- Singapore
- Volunteers
- 750 people
- Sponsor
- KK Women's and Children's Hospital
Breast Cancer
Breast Cancer and Its Relationship With the Microbiota
Breast cancer ranks first in women, and is the second cause of death in this gender. In addition to genetics, the environment contributes to the development of the disease, although the factors involved are not well known.
- Trial name
- MICROMA (NCT03885648)
- Where
- Spain
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Universidad de Granada
Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
This phase I trial studies the side effects and best dose of everolimus and trastuzumab when given together with letrozole in treating patients with hormone receptor-positive and human epidermal growth factor (EGF) receptor 2…
- Conditions
- Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive, HER2/Neu Positive, Postmenopausal
- Trial name
- NCT02152943
- Testing
- Everolimus, Laboratory Biomarker Analysis, Letrozole
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Postoperative Bleeding, Gender Dysphoria
Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy
The purpose of this study is to determine if applying a single dose of topical estrogen cream in the operating room at the end of your hysterectomy (removal of uterus and cervix) improves the postoperative experience with…
- Conditions
- Postoperative Bleeding, Gender Dysphoria, Hysterectomy
- Trial name
- NCT06969326
- Testing
- Use of topical estradiol, No intervention
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Women and Infants Hospital of Rhode Island
Breast Cancer
CIrCuLAting Dna ESr1 Gene Mutations Analysis
The estrogen-dependent nature of breast cancer was first reported in 1896 with the publication of George Beatson's observations on the regression of breast cancer following oophorectomy.
- Trial name
- CICLADES (NCT03318263)
- Testing
- next-generation sequencing (NGS)
- Where
- 10 sites in France
- Volunteers
- 146 people
- Sponsor
- Institut de Cancérologie de Lorraine
Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) breast cancer.
- Conditions
- Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Breast Cancer
- Trial name
- CAPELA (NCT07222215)
- Testing
- Capecitabine, Elacestrant
- Where
- United States
- Volunteers
- 297 people
- Sponsor
- Kristina A. Fanucci